247071-37-0

Basic information

• Product Name: 4-AMino-5-fluoro-2-Methoxy-benzonitrile
• Synonyms: 4-AMino-5-fluoro-2-Methoxy-benzonitrile
• CAS NO: 247071-37-0
• Molecular Formula: C₈H₇FN₂O
• Molecular Weight: 166.1523832
• Mol File: 247071-37-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-AMino-5-fluoro-2-Methoxy-benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMino-5-fluoro-2-Methoxy-benzonitrile(247071-37-0)
• EPA Substance Registry System: 4-AMino-5-fluoro-2-Methoxy-benzonitrile(247071-37-0)

Safety Data

• Hazardous Substances Data: 247071-37-0(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 112279-61-5 4-amino-2,5-difluoro-benzonitrile 

Downstream Products

• 617246-14-7 4-amino-5-fluoro-2-methoxy-benzoic acid methyl ester 
• 325469-46-3 N-(2-fluoro-4-cyano-5-methoxy-phenyl)-phthalimide 
• 1401423-32-2 (4-amino-5-fluoro-2-methoxyphenyl)(morpholino)-methanone 
• 1351761-25-5 (5-fluoro-2-methoxy-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)phenyl)(mor pholino)methanone 
• 1346763-78-7 4-amino-5-fluoro-2-methoxybenzoic acid 

Relevant articles and documents

Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors

There is a high demand for potent, selective, and brain-penetrant small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) to test whether inhibition of LRRK2 kinase activity is a potentially viable treatment option for Parkinson's disease patients. Herein we disclose the use of property and structure-based drug design for the optimization of highly ligand efficient aminopyrimidine lead compounds. High throughput in vivo rodent cassette pharmacokinetic studies enabled rapid validation of in vitro-in vivo correlations. Guided by this data, optimal design parameters were established. Effective incorporation of these guidelines into our molecular design process resulted in the discovery of small molecule inhibitors such as GNE-7915 (18) and 19, which possess an ideal balance of LRRK2 cellular potency, broad kinase selectivity, metabolic stability, and brain penetration across multiple species. Advancement of GNE-7915 into rodent and higher species toxicity studies enabled risk assessment for early development.

NOVEL BENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS

Novel compounds of Formula I which modulate MCH activity are disclosed, in which A is a linker, Ar, is an aryl or heteroaryl group; R1 is hydrogen or a lower alkoxy group; Q together with the carbonyl forms an amide group, which is further substituted with an amine group; R5 is hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups,-CHO, nitrile, alkyl, alkenyl or alkynyl groups,-SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as-CH2CF3,-CF2CF3,-CF3,-OCF3,-SCF3;-SO2NH2,-SO2NHAlk,-SO2NAlk2,-SO2AIk; R8 is hydrogen, halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups, alkylcycloalkyl groups, alkoxy groups, dialkylamino groups,-CONHAIk,-CONAIk2,-NHCO-Alk,-CO-Alk,-SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as-CH2CF3,-CF2CF3,-CF3,-OCF3,-SCF3; X is H, F, Cl, Br, I,-SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as-CH2CF3,-CF2CF3,-CF3,-OCF3,-SCF3; OCH3 or lower alkyl or alkenyl group; and which are useful in the treatment or prevention of e.g. obesity, depression, diabetes, bulimia etc.